Antonio Q. Andrade

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
We present a retrospective evaluation assessing the use of a novel fibrin sealant, Quixil(®) (OMRIX Biopharmaceuticals S.A.) in reducing blood transfusions following revision total hip replacement surgery. Forty four patients underwent revision total hip replacement surgery using Quixil(®), while 45 patients underwent revision total hip replacement surgery(More)
  • 1